Abstract
Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus (T2DM) by reducing renal glucose reabsorption. The aim was to evaluate the lipid effects of dapagliflozin 10 mg or placebo in patients with T2DM with/without baseline elevated triglyceride and reduced high-density lipoprotein (HDL) cholesterol levels. This was a post hoc analysis of 10 phase 3, placebo-controlled studies of dapagliflozin 10 mg (N = 2237) or placebo (N = 2164) administered for 24 weeks in patients with T2DM. Patients with elevated triglyceride (≥150 mg/dL [1.69 mmol/L]) and reduced HDL cholesterol levels (<40 mg/dL [1.04 mmol/L] in men; <50 mg/dL [1.29 mmol/L] in women) were included (group A). The reference group (group B) included patients who did not meet the defined lipid criteria. The effects of dapagliflozin on fasting lipid profiles were generally similar in the 2 lipid groups (ie, groups A and B) and, compared with placebo, were associated with minor increases in non-HDL cholesterol, low-density lipoprotein, and HDL cholesterol levels. The effects on triglyceride levels were inconsistent. The incidence of adverse events (AEs)/serious AEs, and AEs of genital infec...Continue Reading
Citations
Apr 28, 2018·Current Opinion in Cardiology·Kalliopi PafiliNikolaos Papanas
Jan 16, 2019·Expert Review of Clinical Pharmacology·Angelo Maria PattiAli A Rizvi
Apr 22, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nienke M A IdzerdaHiddo J L Heerspink
May 28, 2019·European Cardiology·Juan Tamargo
Apr 1, 2020·Journal of Clinical Medicine·Angelo Maria PattiFerdinando Mannello
Jul 9, 2020·Alimentary Pharmacology & Therapeutics·Margery A ConnellyArun J Sanyal
Aug 29, 2020·Nature Reviews. Endocrinology·André J Scheen
Sep 16, 2019·Current Cardiology Reports·Cezary Wojcik, Bruce A Warden
May 12, 2018·Circulation Research·André J Scheen
Oct 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Sempastian Filippas-NtekouanMoses Elisaf
Dec 1, 2019·Scientific Reports·Jan PennigFlorian Willecke
Jan 14, 2021·Lipids in Health and Disease·Yihai LiuLina Kang
Mar 23, 2021·The Journal of Pharmacy and Pharmacology·Eva KralovaJan Klimas
Oct 26, 2021·The Cochrane Database of Systematic Reviews·Takayoshi KanieJoey Sw Kwong
Oct 3, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G P FadiniUNKNOWN DARWIN-T2D Network